forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Outlook for obesity in 2025: more than a transition year GLP-1 Receptor Agonist Market Size

You might find yourself avoiding outdoor activities, which can affect your physical fitness and mental well-being

These fluctuations can affect GLP-1 medication effectiveness, causing periods of strong appetite suppression followed by periods where the medication seems to stop working

Semaglutide is an appetite suppressor

News that makes sense Your trusted source for staying up-to-date with the world around you

Pictured: Woman grasping her stomach in pain/iStock, Doucefleur The use of glucagon-like peptide 1 (GLP-1) agonists for weight loss, such as Novo Nordisks Ozempic and Wegovy, is associated with the risk of gastrointestinal adverse events, according to a study published Thursday in the medical journal JAMA